Takeda Pharmaceuticals: Global Homepage

Takeda leads with a generational promise

to boldly reinvent for a healthier world

Unlocking a new era of impact with first-in-class treatments.

FDA approves Takeda’s narcolepsy type 1 medicine

A new chapter for narcolepsy type 1 (NT1) care and orexin science

We expect to make this first-in-class medicine available to the NT1 community by November 2026, pending U.S. Drug Enforcement Administration scheduling.

Learn more

Our Stories

View all stories

An adult and a child reading a book in a forest

Recent News

View all news

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

August 5, 2026

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track

July 30, 2026

Takeda’s ORZEYFUL (oveporexton) Approved in China as First Orexin Agonist and Only Medicine to Treat Narcolepsy Type 1

July 22, 2026

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies

July 16, 2026

Learn more about Takeda

Join Us

Work with globally diverse colleagues who are committed to challenging one another to achieve more together.

Learn more

Investors

Discover how we're unlocking growth potential through bold innovation and a robust pipeline.

Learn more

R&D

We’re translating cutting-edge science into therapies that address urgent patient needs and create new standards of care.

Learn more

Sign up for investors newsletter

Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet

Sign up

Takeda Pharmaceuticals: Global Homepage

TakedaEdgeTakeda leads with a generational promise

Unlocking a new era of impact with first-in-class treatments.

FDA approves Takeda’s narcolepsy type 1 medicine

Our Stories

Driving innovation in plasma-derived therapies

Setting a new testing standard in the battle against polio

Finding the Words: How an EoE Diagnosis Changed One Family’s Outlook

Recent News

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track

Takeda’s ORZEYFUL (oveporexton) Approved in China as First Orexin Agonist and Only Medicine to Treat Narcolepsy Type 1

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies

Join Us

Investors

R&D

Sign up for investors newsletter

Takeda leads with a generational promise

Takeda’s ORZEYFUL (oveporexton) Approved in China as First Orexin Agonist and Only Medicine to Treat Narcolepsy Type 1